Doximity, Inc. (DOCS)
Doximity, Inc. operates a digital platform for medical professionals in the United States. Its Doximity platform includes a personalized newsfeed that presents clinical and professional content to members, which offers medical articles, clinical trials or research results in an easy-to-consume video format, professional updates and accomplishments of their peers and colleagues, clinical discussions, Op-Med articles for publication, and sponsored content from pharmaceutical manufacturers and health systems. The company also offers workflow tools, including Ask, a HIPAA-compliant AI assistant, to access and apply evidence-based medical information within clinical workflows; Scribe, a HIPAA-compliant, AI-powered clinical documentation tool; Telehealth tools for hospitals and health systems; and AMiON, an on-call scheduling tool. The company primarily serves physicians, nurse practitioners, physician assistants, medical students, pharmaceutical manufacturers, and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
- Symbol
- DOCS
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Health Information Services
- Market cap
- $4.78B
- 52 week range
- 17.15 - 76.51
Valuation
- Share price
- $26.57 (close of 2026-09-23)
- P/E (TTM)
- 29.52x
- Price to book
- 5.22x
- Price to free cash flow
- 15.60x
- Enterprise value
- $4.51B
- Book value per share
- $5.09
Price performance
| Period | Change |
|---|
| 1 day | -1.01% |
| 5 days | +2.94% |
| 1 month | +4.90% |
| 3 months | +29.74% |
| 6 months | +6.15% |
| Year to date | -40.00% |
| 1 year | -64.05% |
| 3 years | +33.58% |
| 5 years | -69.84% |
| All time | -49.87% |
Profitability and growth
- Return on equity
- 20.62%
- Return on invested capital
- 21.70%
- Return on assets
- 17.45%
- Return on capital employed
- 22.19%
- Gross margin
- 89.09%
- Net margin
- 30.40%
- EBITDA margin
- 35.56%
- Revenue growth
- 13.05%
- Net income growth
- -12.16%
- Free cash flow growth
- 19.47%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 6.41%
- Current ratio
- 6.08x
- Net debt to EBITDA
- -1.26x
Latest reported year
- Period end
- 2026-03-31
- Fiscal year
- 2026
- Revenue
- $644.86M
- Cost of revenue
- $70.33M
- Gross profit
- $574.54M
- EBITDA
- $229.30M
- Net income
- $196.05M
- Earnings per share
- $1.05
- Research and development
- $130.70M
- Shares outstanding
- 187.01M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2026-03-31 | $644.86M | $574.54M | $196.05M | $1.05 |
| 2025-03-31 | $570.40M | $514.52M | $223.19M | $1.19 |
| 2024-03-31 | $475.42M | $424.75M | $147.58M | $0.78 |
| 2023-03-31 | $419.05M | $365.56M | $112.82M | $0.58 |
| 2022-03-31 | $343.55M | $303.76M | $154.78M | $0.82 |
| 2021-03-31 | $206.90M | $175.70M | $50.21M | $0.29 |
| 2020-03-31 | $116.39M | $101.49M | $29.74M | $0.16 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2026-03-31 | 89.09% | 30.40% | 20.62% | 21.70% |
| 2025-03-31 | 90.20% | 39.13% | 20.62% | 21.17% |
| 2024-03-31 | 89.34% | 31.04% | 16.37% | 15.41% |
| 2023-03-31 | 87.24% | 26.92% | 11.68% | 60.73% |
| 2022-03-31 | 88.42% | 45.05% | 17.62% | 66.16% |
| 2021-03-31 | 84.92% | 24.27% | 75.23% | 2851.87% |
| 2020-03-31 | 87.20% | 25.55% | 2617.69% | - |
Cash and debt by year
| Period end | Cash |
|---|
| 2026-03-31 | $219.18M |
| 2025-03-31 | $209.61M |
| 2024-03-31 | $96.78M |
| 2023-03-31 | $809.25M |
| 2022-03-31 | $708.06M |
| 2021-03-31 | $66.39M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2026-03-31 | $326.46M | $121.63M |
| 2025-03-31 | $273.26M | $72.39M |
| 2024-03-31 | $183.95M | $51.08M |
| 2023-03-31 | $177.90M | $47.83M |
| 2022-03-31 | $124.66M | $31.44M |
| 2021-03-31 | $82.73M | $7.25M |
| 2020-03-31 | $25.91M | $2.35M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-05
- Consensus EPS estimate
- $0.19
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-06 | Jun/2026 | $0.16 |
| 2026-05-13 | - | - |
| 2026-02-05 | - | - |
| 2025-11-06 | - | - |
| 2025-08-07 | - | - |
| 2025-05-15 | - | - |
| 2025-05-14 | - | - |
| 2025-02-06 | - | - |
Filings and sources
- Company website
- doximity.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades